UK myeloma access study spotlights funding barriers

New qualitative research from Colait says access to advanced multiple myeloma therapies in the United Kingdom is still shaped more by funding and logistics than by clinical evidence. The findings point to NICE guidance, center-to-center variation, and clinical trials as key gatekeepers for patients.

Why it matters: - Access to advanced multiple myeloma treatments in the UK can depend more on reimbursement and local capacity than on clinical need. - The findings highlight how funding rules can limit individualized care even when newer therapies have strong evidence behind them. - The research also shows that clinical trials remain a critical route to innovation for some patients in NHS care.

What happened: - Colait released new qualitative research on multiple myeloma access and treatment decision-making in the UK. - The study surveyed consultant hematologists across tertiary and academic centers. - Respondents said NICE guidance and reimbursement criteria largely determine treatment selection within the NHS. - Clinicians reported that access to novel therapies varies widely by center. - The research found that clinical trials often provide the main path to advanced treatment for patients who do not qualify under standard NHS pathways.

The details: - Participants identified funding policies, institutional capacity, and logistical barriers as major constraints on access to advanced therapies. - The survey found limited flexibility for clinicians to tailor care within existing NHS funding pathways. - NICE has since expanded access to multiple bispecific antibody therapies and broadened eligibility criteria after advocacy from clinicians and patient groups. - Those changes support the study’s central point that reimbursement decisions remain a major driver of patient access to innovative care. - Colait funded the study as part of its effort to capture and amplify real-world clinical expert opinion in fast-changing therapeutic areas. - Colette Balaam, Colait’s CEO, said the research was designed to capture clinician perspectives at scale and surface practical challenges and opportunities that shape routine treatment decisions. - Full findings, including thematic analysis and additional quantitative insights, will be presented at a major international hematology meeting later this year.

Between the lines: - The study suggests policy change can move access faster than clinical adoption alone. - NICE’s expanded coverage shows clinician and patient advocacy can open doors to newer therapies, but access still appears uneven. - Colait is positioning its platform around structured clinician insight, which may appeal to life sciences companies looking to understand real-world barriers.

What's next: - Colait plans to present the full study at a major international hematology meeting later this year. - Further NICE decisions and advocacy efforts could continue to shape who gets access to bispecific antibodies and other advanced myeloma treatments. - The research may add pressure for more consistent access across UK treatment centers.